Sinopep-Allsino Bio Pharmaceutical (688076) Fundamentals 2026 — P/E 27.8x, Revenue Analysis | SniperIQ
Sinopep-Allsino Bio Pharmaceutical (688076) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥8.5B, trading at ¥26.92 on the SHH. This SniperIQ fundamentals page covers Sinopep-Allsino Bio Pharmaceutical's valuation (P/E 27.8x, P/B 2.7x), profitability (net margin 15.7%), revenue (¥1.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sinopep-Allsino Bio Pharmaceutical's market cap?
Sinopep-Allsino Bio Pharmaceutical (688076) has a market capitalization of approximately ¥8.5B, trading at ¥26.92 on the SHH. Market cap moves with the live share price.
What is Sinopep-Allsino Bio Pharmaceutical's P/E ratio?
Sinopep-Allsino Bio Pharmaceutical's trailing twelve-month P/E ratio is 27.8x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sinopep-Allsino Bio Pharmaceutical?
Sinopep-Allsino Bio Pharmaceutical runs a net profit margin of 15.7%, a gross margin of 97.8%, and an operating margin of 20.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sinopep-Allsino Bio Pharmaceutical generate?
Sinopep-Allsino Bio Pharmaceutical reported revenue of ¥1.9B for fiscal year 2025, with net income of ¥332M and earnings per share (EPS) of 1.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sinopep-Allsino Bio Pharmaceutical pay a dividend?
Sinopep-Allsino Bio Pharmaceutical offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sinopep-Allsino Bio Pharmaceutical financially healthy?
Sinopep-Allsino Bio Pharmaceutical carries a debt-to-equity ratio of 0.95x and a current ratio of 1.17x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sinopep-Allsino Bio Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sinopep-Allsino Bio Pharmaceutical (688076) the key facts are: market cap ¥8.5B, P/E 27.8x, revenue ¥1.9B, 52-week range 25.7-50.86. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sinopep-Allsino Bio Pharmaceutical's full fundamentals live
Get Sinopep-Allsino Bio Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.